NASDAQ:NVAXNovavax Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Novavax, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $134.84 +10.42 (+8.37 %) (As of 08/13/2020 03:36 PM ET) Add Compare Share Today's Range$117.39Now: $134.84▼$140.7050-Day Range$69.66MA: $120.50▼$178.5152-Week Range$3.54Now: $134.84▼$189.40Volume261,495 shsAverage Volume8.84 million shsMarket Capitalization$7.82 billionP/E RatioN/ADividend YieldN/ABeta1.75 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Novavax, Inc., together with its subsidiary, Novavax AB, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. The company's lead vaccine candidates include ResVax, a respiratory syncytial virus (RSV) fusion (F) protein recombinant nanoparticle vaccine with aluminum phosphate as an adjuvant that is in Phase III clinical trial to protect infants from RSV disease through maternal immunization; and NanoFlu, which is in Phase II clinical trial for treating seasonal influenza in older adults. Its lead adjuvant is Matrix-M that is used to enable a vaccine to enhance the amplitude of the immune response and qualitatively change it, and the immune systems attack against microorganisms, as well as allows immunization with much lower doses of antigen. The company also develops RSV F vaccine for older adults in Phase II clinical trial, and healthy children between two and six years of age in Phase I clinical trial. In addition, it develops nanoparticle vaccine candidates for clinic testing against ebola virus in Phase I clinical trial, as well as MERS coronavirus in animals; and combination respiratory vaccine to protect against influenza and RSV. The company has a clinical development agreement with Bill & Melinda Gates Foundation. Novavax, Inc. was founded in 1987 and is headquartered in Gaithersburg, Maryland.Read More Beat the Market (BTM) Rank™ 2.4 Analyst's Opinion Consensus RatingNovavax has received a consensus rating of Buy. The company's average rating score is 2.71, and is based on 6 buy ratings, no hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $124.07, Novavax has a potential downside of 6.5% from its current price of $132.71.Amount of Analyst CoverageNovavax has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.1 Community Rank Outperform VotesNovavax has received 801 “outperform” votes. (Add your “outperform” vote.)Underperform VotesNovavax has received 479 “underperform” votes. (Add your “underperform” vote.)Community SentimentNovavax has received 62.58% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Novavax and other stocks. Vote “Outperform” if you believe NVAX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe NVAX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldNovavax does not currently pay a dividend.Dividend GrowthNovavax does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Novavax insiders have sold 1,261.28% more of their company's stock than they have bought. Specifically, they have bought $73,245.00 in company stock and sold $997,068.00 in company stock.Percentage Held by InsidersOnly 1.60% of the stock of Novavax is held by insiders.Percentage Held by InstitutionsOnly 22.64% of the stock of Novavax is held by institutions. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Novavax are expected to grow by 198.78% in the coming year, from $5.75 to $17.18 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Novavax is -32.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Novavax is -32.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 2.4Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.9 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.47 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:NVAX Previous Symbol CUSIP67000210 CIK1000694 Webwww.novavax.com Phone240-268-2000Debt Debt-to-Equity RatioN/A Current Ratio13.45 Quick Ratio13.45Price-To-Earnings Trailing P/E RatioN/A Forward P/E Ratio23.45 P/E GrowthN/A Sales & Book Value Annual Sales$18.66 million Price / Sales418.82 Cash FlowN/A Price / Cash FlowN/A Book Value($5.75) per share Price / Book-23.45Profitability EPS (Most Recent Fiscal Year)($5.80) Net Income$-132,690,000.00 Net Margins-638.76% Return on EquityN/A Return on Assets-57.28%Miscellaneous Employees373 Outstanding Shares57,959,000Market Cap$7.82 billion Next Earnings Date11/5/2020 (Estimated) OptionableOptionable $134.84 +10.42 (+8.37 %) (As of 08/13/2020 03:36 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive NVAX News and Ratings via Email Sign-up to receive the latest news and ratings for NVAX and its competitors with MarketBeat's FREE daily newsletter. Novavax (NASDAQ:NVAX) Frequently Asked Questions How has Novavax's stock price been impacted by Coronavirus? Novavax's stock was trading at $10.51 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, NVAX stock has increased by 1,158.9% and is now trading at $132.31. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Novavax? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novavax in the last year. There are currently 1 sell rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Novavax. When is Novavax's next earnings date? Novavax is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020. View our earnings forecast for Novavax. How were Novavax's earnings last quarter? Novavax, Inc. (NASDAQ:NVAX) announced its quarterly earnings results on Monday, August, 10th. The biopharmaceutical company reported ($0.30) earnings per share for the quarter, topping analysts' consensus estimates of ($0.60) by $0.30. The biopharmaceutical company earned $35.50 million during the quarter, compared to the consensus estimate of $5.67 million. The business's quarterly revenue was up 944.1% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($1.69) earnings per share. View Novavax's earnings history. When did Novavax's stock split? How did Novavax's stock split work? Shares of Novavax reverse split on Friday, May 10th 2019. The 1-20 reverse split was announced on Wednesday, May 8th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 9th 2019. An investor that had 100 shares of Novavax stock prior to the reverse split would have 5 shares after the split. What price target have analysts set for NVAX? 7 brokerages have issued 1 year target prices for Novavax's stock. Their forecasts range from $15.00 to $275.00. On average, they expect Novavax's stock price to reach $124.07 in the next year. This suggests that the stock has a possible downside of 6.2%. View analysts' price targets for Novavax. Has Novavax been receiving favorable news coverage? Media coverage about NVAX stock has trended extremely negative recently, according to InfoTrie Sentiment. The research group identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Novavax earned a news sentiment score of -4.1 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the near future. View the latest news about Novavax. Are investors shorting Novavax? Novavax saw a increase in short interest in May. As of May 15th, there was short interest totaling 7,360,000 shares, an increase of 28.9% from the April 30th total of 5,710,000 shares. Based on an average trading volume of 10,890,000 shares, the short-interest ratio is presently 0.7 days. View Novavax's Short Interest. Who are some of Novavax's key competitors? Some companies that are related to Novavax include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU) and Repligen (RGEN). View all competitors. What other stocks do shareholders of Novavax own? Based on aggregate information from My MarketBeat watchlists, some companies that other Novavax investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Egalet (EGLT), Palo Alto Networks (PANW), NVIDIA (NVDA), EXACT Sciences (EXAS), Moderna (MRNA), Akebia Therapeutics (AKBA), Advanced Micro Devices (AMD) and Pfizer (PFE). Who are Novavax's key executives? Novavax's management team includes the following people: Mr. Stanley Charles Erck, Pres, CEO & Director (Age 71)Mr. John Joseph Trizzino, Sr. VP, Chief Bus. Officer, CFO & Treasurer (Age 59)Mr. John A. Herrmann III, Sr. VP, Gen. Counsel & Corp. Sec. (Age 53)Dr. Gregory M. Glenn, Pres of R&D (Age 65)Ms. Erika S. Trahan, Sr. Mang. of Investor & PR What is Novavax's stock symbol? Novavax trades on the NASDAQ under the ticker symbol "NVAX." Who are Novavax's major shareholders? Novavax's stock is owned by a number of retail and institutional investors. Top institutional investors include Bank of New York Mellon Corp (0.51%), Goldman Sachs Group Inc. (0.34%), California Public Employees Retirement System (0.22%), Swiss National Bank (0.20%), State of Wisconsin Investment Board (0.16%) and Creative Planning (0.16%). Company insiders that own Novavax stock include Gregory M Glenn, James F Young, John A Herrmann III, John Trizzino, Michael A Mcmanus Jr and Rachel K King. View institutional ownership trends for Novavax. Which major investors are selling Novavax stock? NVAX stock was sold by a variety of institutional investors in the last quarter, including TSP Capital Management Group LLC, Goldman Sachs Group Inc., Beirne Wealth Consulting Services LLC, UBS Group AG, Leap Investments LP, Commonwealth Equity Services LLC, and Sargent Investment Group LLC. Company insiders that have sold Novavax company stock in the last year include Gregory M Glenn, John A Herrmann III, John Trizzino, and Michael A Mcmanus Jr. View insider buying and selling activity for Novavax. Which major investors are buying Novavax stock? NVAX stock was purchased by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Swiss National Bank, California Public Employees Retirement System, Virtu Financial LLC, State of Wisconsin Investment Board, Barclays PLC, EAM Investors LLC, and New York State Common Retirement Fund. Company insiders that have bought Novavax stock in the last two years include Gregory M Glenn, James F Young, and Rachel K King. View insider buying and selling activity for Novavax. How do I buy shares of Novavax? Shares of NVAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Novavax's stock price today? One share of NVAX stock can currently be purchased for approximately $132.31. How big of a company is Novavax? Novavax has a market capitalization of $7.67 billion and generates $18.66 million in revenue each year. The biopharmaceutical company earns $-132,690,000.00 in net income (profit) each year or ($5.80) on an earnings per share basis. Novavax employs 373 workers across the globe. What is Novavax's official website? The official website for Novavax is www.novavax.com. How can I contact Novavax? Novavax's mailing address is 21 FIRSTFIELD ROAD, GAITHERSBURG MD, 20878. The biopharmaceutical company can be reached via phone at 240-268-2000 or via email at [email protected] This page was last updated on 8/13/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
